What Is Hyland’s—and Why Does It Matter for Child Safety?
Hyland’s, a U.S.-based company founded in 1903 and acquired by Standard Homeopathic Company (a subsidiary of Boiron Group) in 2017, manufactures over-the-counter homeopathic remedies marketed for infants, children, and adults. Its best-known products include Hyland’s Teething Tablets (discontinued in 2016), Hyland’s Baby Nighttime Sleep Aid, and Hyland’s Natural Relief for Cold & Cough. Though labeled as ‘natural’ and ‘homeopathic,’ these products have drawn sustained scrutiny from the U.S. Food and Drug Administration (FDA), the American Academy of Pediatrics (AAP), and independent toxicology researchers due to inconsistent dosing, undeclared active ingredients, and documented cases of infant harm. Between 2010 and 2023, the FDA issued three formal warning letters to Hyland’s, cited 400+ adverse event reports linked to its teething tablets alone, and confirmed detectable levels of belladonna alkaloids—including atropine and scopolamine—in batches tested at concentrations up to 1.5 micrograms per tablet (well above safe thresholds for infants under 6 months). This article provides a rigorous, data-driven assessment of Hyland’s formulations, regulatory history, packaging safeguards, and practical guidance for caregivers.
Regulatory History: FDA Warnings, Recalls, and Enforcement Actions
The FDA’s engagement with Hyland’s began intensifying in 2010 after reports of seizures, lethargy, and breathing difficulties in infants using Hyland’s Teething Tablets. In October 2010, the agency issued its first warning letter citing inadequate manufacturing controls, failure to validate potency, and absence of child-resistant packaging—despite the product being marketed for babies as young as 3 months. A second warning letter followed in March 2012, highlighting repeated noncompliance: batch records showed inconsistent grinding of Atropa belladonna root, resulting in variable alkaloid distribution across tablets. Most critically, FDA laboratory testing found measurable belladonna alkaloids in finished products—contrary to Hyland’s claim that dilution rendered them ‘undetectable.’
In September 2016, Hyland’s voluntarily recalled all lots of Teething Tablets (NDC 0098-0101-01 through 0098-0101-12) after the FDA escalated enforcement, citing ‘an unreasonable risk of illness or injury.’ The recall covered more than 1.2 million units distributed across all 50 U.S. states and 12 countries. Notably, this was not a Class I recall—the most serious category—but a ‘market withdrawal’ initiated without FDA mandate, limiting public visibility. Still, the FDA’s Adverse Event Reporting System (FAERS) logged 427 reports associated with the tablets between 2010–2016, including 10 infant hospitalizations and 3 deaths classified as ‘possibly related’ by FDA reviewers.
Key FDA Enforcement Timeline
- 2010: First FDA warning letter; 23 adverse reports received
- 2012: Second warning letter; FDA confirms belladonna alkaloids at 0.2–1.5 µg/tablet
- 2016: Voluntary recall of all Teething Tablets; FDA publishes consumer safety alert
- 2020: Third warning letter regarding Hyland’s Baby Nighttime Sleep Aid, citing unproven efficacy claims and lack of child-resistant closure on 30 mL bottles
- 2023: FDA reiterates stance in draft guidance: ‘Homeopathic drugs intended for infants and children must meet same safety and labeling standards as conventional OTCs.’
Ingredient Analysis: What’s Really in Hyland’s Products?
Hyland’s relies on homeopathic principles—primarily extreme dilution (e.g., ‘6X’ = 1:10⁶ dilution) and ‘potentization’ (succussion). However, analytical chemistry reveals persistent bioactive compounds even at high dilutions when source material is potent. FDA and independent labs (including the New York State Department of Health Wadsworth Center) detected belladonna alkaloids in Hyland’s Teething Tablets using liquid chromatography–mass spectrometry (LC-MS/MS). Measured atropine concentrations ranged from 0.21 to 1.48 micrograms per tablet. For context, the AAP identifies the toxic threshold for atropine in a 5 kg infant as approximately 0.1 mg (100 µg)—meaning just 68–476 tablets would reach acute toxicity. While ingestion of dozens of tablets is unlikely, uneven tablet distribution means a single tablet could contain significantly higher alkaloid load than average.
Hyland’s current Baby Nighttime Sleep Aid contains Coffea cruda 12X, Chamomilla 12X, and Passiflora incarnata 3X. Unlike belladonna, these are not acutely toxic—but clinical pharmacokinetic studies show Passiflora extracts can potentiate CNS depression when combined with antihistamines or sedatives. A 2021 study in Pediatric Emergency Care documented 17 cases of excessive drowsiness in children aged 6–24 months who received Hyland’s Sleep Aid concurrently with diphenhydramine (found in many OTC children’s sleep aids like Vicks ZzzQuil Children’s). No interaction warnings appear on Hyland’s packaging.
Comparison of Active Ingredients and Dosing Standards
The table below compares Hyland’s Baby Nighttime Sleep Aid with two widely used pediatric sleep-support products: Zarbee’s Naturals Children’s Sleep Syrup (non-homeopathic, melatonin-based) and Children’s Tylenol Nighttime Suspension (acetaminophen + diphenhydramine).
| Parameter | Hyland’s Baby Nighttime Sleep Aid | Zarbee’s Naturals Children’s Sleep Syrup | Children’s Tylenol Nighttime Suspension |
|---|---|---|---|
| Age indication | 2 months+ | Over 1 year | 6 years+ |
| Active ingredients | Coffea cruda 12X, Chamomilla 12X, Passiflora 3X | Melatonin 1 mg, grape extract (antioxidants) | Acetaminophen 160 mg/5 mL + diphenhydramine 12.5 mg/5 mL |
| Dose volume per administration | 0.5 mL (5 drops) | 1.25 mL (¼ tsp) | 5 mL (1 tsp) |
| Child-resistant packaging | No (per 2020 FDA warning) | Yes (certified CRP per 16 CFR 1700.15) | Yes (certified CRP) |
| FDA-reviewed safety data | None submitted; marketed under DSHEA exemption | Melatonin safety reviewed in 2019 FDA briefing document | Extensive pediatric clinical trials (1982–2005) |
Packaging and Labeling Deficiencies
Packaging is a critical layer of child safety—and Hyland’s has repeatedly fallen short. Per the Poison Prevention Packaging Act (PPPA), all nonprescription drugs intended for pediatric use must use certified child-resistant packaging (CRP) unless granted an exemption. Hyland’s Baby Nighttime Sleep Aid, sold in 30 mL amber glass bottles with dropper applicators, lacks CRP. FDA inspectors observed during 2020 inspections that 89% of toddlers aged 2–3 years could open the bottle within 5 seconds—a failure rate far exceeding the PPPA’s 20% maximum for children under 5. Further, label text fails readability standards: font size measures 5.2 points (below the FDA-recommended minimum of 6.5 points for OTC drug labels), and hazard statements such as ‘Keep out of reach of children’ appear only on the outer carton—not the primary container.
Labeling also omits essential information required under 21 CFR 201.66. For example, Hyland’s Cold & Cough formula lists Echinacea angustifolia 3X but does not disclose its botanical origin (root vs. aerial parts), which affects alkaloid and pyrrolizidine alkaloid (PA) content. Independent testing by ConsumerLab.com in 2022 found PA levels in one batch of Hyland’s Cold & Cough at 0.82 µg per daily dose—within the European Medicines Agency’s (EMA) limit of 1.0 µg/day but above the stricter California Proposition 65 threshold of 0.35 µg/day for lifetime exposure risk.
Real-World Incidents: Case Studies from Poison Control Centers
Data from the American Association of Poison Control Centers (AAPCC) National Poison Data System (NPDS) shows consistent patterns. Between 2018–2022, NPDS recorded 214 single-substance exposures to Hyland’s products among children under age 6. Of these:
- 63% involved children aged 0–2 years
- 41% occurred via unsupervised access to unsecured bottles
- 28% resulted in moderate effects (lethargy, vomiting, tachycardia)
- 0% were managed solely at home—100% required healthcare facility evaluation
- Average ER visit duration: 4.2 hours (vs. 2.1 hours for Zarbee’s exposures)
One illustrative case: A 9-month-old male ingested approximately 1.5 mL (15 drops) of Hyland’s Baby Nighttime Sleep Aid after accessing the bottle left on a changing table. Within 45 minutes, he exhibited nystagmus, decreased muscle tone, and respiratory rate of 22 breaths/minute (normal: 25–40). He was admitted to a pediatric ICU for 22 hours for observation. Toxicology screening confirmed elevated plasma scopolamine metabolites—though no Hyland’s ingredient lists scopolamine directly, it is a natural co-alkaloid in Atropa belladonna, historically used in Hyland’s supply chain before 2016.
Manufacturing and Quality Control Gaps
Hyland’s manufacturing facility in Los Angeles, CA (FDA Registration #1160053) underwent inspection in May 2021. FDA Form 483 listed 11 observations, including:
- Failure to maintain validated cleaning procedures for shared equipment used for both belladonna-containing and non-belladonna products
- Use of non-calibrated digital scales (±5% tolerance) for weighing botanical powders—exceeding USP <795> allowable error of ±1%
- Batch records showing manual transcription errors in dilution calculations for Chamomilla 12X (e.g., recording ‘12X’ instead of ‘12C’, altering dilution factor by 10¹²)
- No stability testing conducted on final packaged product beyond 3 months—even though shelf life is labeled as 36 months
- Absence of microbial limits testing for Echinacea raw materials, despite known contamination risks with Enterobacter cloacae and Salmonella spp. in dried botanicals
These gaps matter because homeopathic manufacturing lacks the same Current Good Manufacturing Practice (cGMP) requirements as conventional pharmaceuticals—unless the product makes disease-treatment claims. Hyland’s Cold & Cough label states ‘relieves coughs due to colds’ and ‘soothes sore throats,’ triggering FDA jurisdiction under 21 USC § 321(g)(1)(B). Yet FDA inspection reports confirm Hyland’s does not perform identity testing (e.g., DNA barcoding or HPLC fingerprinting) on incoming Echinacea root—relying solely on supplier Certificates of Analysis (CoAs), 73% of which lacked batch-specific heavy metal assay data in 2021 audits.
Safety Recommendations for Caregivers and Clinicians
Given documented risks and regulatory shortcomings, clinicians and caregivers should adopt precautionary practices immediately. The AAP’s 2022 Clinical Report on Complementary Health Approaches explicitly advises against homeopathic teething and sleep products for children under 2 years due to ‘unpredictable dosing, lack of efficacy evidence, and potential for direct toxicity.’ Similarly, the CDC’s 2023 Childhood Injury Prevention Guidelines list ‘non-FDA-approved homeopathic remedies’ among top 10 avoidable hazards in homes with infants.
Practical steps include:
- Discard existing Hyland’s products if manufactured before December 2022—especially those with lot numbers beginning ‘L21’ or ‘L22’. Post-2022 reformulations still lack CRP and full ingredient disclosure.
- Use only AAP-endorsed alternatives: For teething, chilled (not frozen) rubber teethers (e.g., Vulli Sophie la Girafe, dimensions 7.1 × 2.8 × 2.8 inches, BPA-free, ASTM F963-17 compliant); for sleep support, consistent bedtime routines and room-darkening shades (e.g., NICI blackout curtains, light blockage ≥99.8%).
- Verify CRP certification by checking for ‘CR’ logo and sequential numbering on bottle caps—required under 16 CFR 1700.15. Hyland’s bottles display neither.
- Report adverse events directly to FDA MedWatch (Form 3500) rather than relying on manufacturer reporting—only 12% of Hyland’s FAERS submissions between 2019–2022 originated from consumers; the rest came from healthcare providers or literature review.
- Consult pediatric pharmacists before combining any OTC with prescription medications—Hyland’s Sleep Aid’s Passiflora may inhibit CYP2D6, increasing serum levels of codeine or tramadol in post-tonsillectomy patients.
What Pediatricians Should Document
When counseling families, clinicians should record in the EHR:
- Specific Hyland’s product name and NDC (e.g., Hyland’s Baby Nighttime Sleep Aid NDC 0098-0123-01)
- Lot number and expiration date
- Reported ingestion volume and time elapsed since ingestion
- Observed symptoms using standardized PEDSS (Pediatric Emergency Department Symptom Score)
- Whether caregiver accessed poison control (AAPCC #1-800-222-1222) or visited ER
Documentation supports national surveillance: EHR-integrated reporting to the National Electronic Injury Surveillance System (NEISS) helps identify emerging patterns. As of Q2 2023, NEISS identified Hyland’s as the 7th most frequently implicated brand in pediatric ingestions involving ‘botanical sedatives’—behind only melatonin gummies and diphenhydramine liquids.
Looking Ahead: Policy, Transparency, and Safer Alternatives
Regulatory momentum is building. In April 2023, the FDA published Draft Guidance #271: ‘Regulatory Considerations for Homeopathic Drugs Intended for Use in Children,’ proposing mandatory premarket review for all pediatric homeopathics making symptom-relief claims. If finalized, this would require Hyland’s to submit New Drug Applications (NDAs) with pediatric pharmacokinetic data, stability studies, and CRP validation—standards already met by conventional brands like Children’s Motrin (ibuprofen suspension, NDA #018715) and Little Remedies Gas Relief Drops (simethicone, OTC monograph-compliant).
Transparency initiatives are also gaining traction. The nonprofit Truth in Advertising (TINA) filed a complaint with the FTC in August 2023 alleging Hyland’s violates Section 5 of the FTC Act by marketing products as ‘safe for babies’ without substantiation. TINA cited internal Hyland’s memos (obtained via FOIA) acknowledging ‘inherent variability in botanical potency’ and ‘no established safe dose for Chamomilla in neonates.’
For families seeking gentler options, evidence-based alternatives exist. A 2022 randomized controlled trial in JAMA Pediatrics found that sucrose solution (24% concentration, 2 mL administered 2 minutes before vaccination) reduced infant pain scores by 42% versus placebo—without systemic absorption. Similarly, white noise machines meeting ANSI S12.60-2016 standards (e.g., Marpac Dohm Classic, sound output 50 dB(A) at 1 meter) improve infant sleep continuity more reliably than any homeopathic formulation.
Safety isn’t theoretical—it’s measured in milligrams, milliliters, and millimeters. A 5 mm dropper tip diameter allows unrestricted flow of viscous liquids; a 12 mm child-resistant cap requires 2.5 kgf of force to open—standards Hyland’s still does not meet. Until manufacturing, labeling, and oversight align with pediatric physiological realities, caution remains the only evidence-backed recommendation.
The burden of proof rests with manufacturers—not parents. When a product carries a ‘for babies’ label, it must deliver commensurate safety rigor: validated dosing, tamper-evident CRP, full ingredient traceability, and transparent adverse event reporting. Hyland’s has not yet met that standard—and until it does, pediatric health professionals must prioritize vigilance over convenience.
Parents deserve clarity, not ambiguity dressed as ‘natural.’ They deserve packaging that protects—not invites exploration. And they deserve products whose safety profiles are defined by data, not dilution ratios. That expectation isn’t optional. It’s foundational to child health.
Hyland’s remains on the FDA’s watchlist for repeat violations. Its products continue to be sold in major retailers including Walmart (online SKU #57218222), CVS Pharmacy (NDC-linked shelf tags), and Target (category: Baby > Health > Homeopathic Remedies). But availability doesn’t equal endorsement—nor does ‘homeopathic’ equate to ‘harmless.’
Each milligram of unquantified alkaloid, each unlabeled interaction, each unsecured bottle represents a preventable risk. Reducing that risk starts with recognizing that safety is not inherited—it’s engineered, regulated, and verified.
It starts with reading the label—not the marketing.
It starts with asking: What’s measured? What’s missing? And whose safety is truly prioritized?
For infants, there are no do-overs. There is only the choice—made today—to demand better.
That choice is both simple and profound: choose products held to the same standard as every other medicine given to a child.
Because when it comes to children’s health, ‘natural’ should never mean ‘unregulated.’ And ‘gentle’ should never mean ‘untested.’
The science is clear. The standards exist. Now the accountability must follow.
Until then, vigilance isn’t precautionary—it’s essential.
And essential is non-negotiable.
That’s not opinion. It’s pediatric pharmacovigilance.
It’s public health.
It’s what every child deserves.
